With the AMLA set to start operations in Frankfurt this summer, law firms with offices in the city will have an advantage, ...
February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...
IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...
IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback